Home>>Signaling Pathways>> JAK/STAT Signaling>> STAT>>inS3-54A18

inS3-54A18

Catalog No.GC32862

inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties.

Products are for research use only. Not for human use. We do not sell to patients.

inS3-54A18 Chemical Structure

Cas No.: 328998-53-4

Size Price Stock Qty
10mM (in 1mL DMSO)
$122.00
In stock
2mg
$101.00
In stock
5mg
$147.00
In stock
10mg
$239.00
In stock
50mg
$873.00
In stock
100mg
$1,471.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties.

inS3-54A18 (5 μM) reduces wound healing to 64% and 76% for A549 and MDA-MB-231 cells, respectively. inS3-54A18 at 10 μM further reduces the healing to 47% and 39%, respectively. inS3-54A18 inhibits the expression of STAT3 downstream target genes and the binding of STAT3 to its endogenous target sequences. inS3-54A18 does not affect the constitutive or IL-6-induced STAT3 activation (Tyr705 phosphorylation) but represses STAT3 target gene (survivin) expression[1].

inS3-54A18 (200 mg/kg, p.o.) inhibits tumor growth, metastasis and expression of STAT3 target genes in a mouse xenograft model of A549 cells[1].

[1]. Huang W, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016 Feb 11;35(6):783-92

Reviews

Review for inS3-54A18

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for inS3-54A18

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.